Metformin in type 2 diabetes: Evidence for its beneficial effects on frailty and sarcopenia

Curr Diabetes Rev. 2023 Jul 27. doi: 10.2174/1573399820666230727101141. Online ahead of print.ABSTRACTThis narrative review aimed to discuss the potential interplay among frailty syndrome, sarcopenia and metformin in type 2 diabetes mellitus (T2DM). There is emerging evidence on the potential protective role of metformin on both frailty and sarcopenia. However, results are not always consistent. Thus, further research is needed to provide a definitive answer on any role of metformin in improving frailty and/or sarcopenia in T2DM.PMID:37497698 | DOI:10.2174/1573399820666230727101141
Source: Current Diabetes Reviews - Category: Endocrinology Authors: Source Type: research